As the federal government moves away from animal experimentation, startup R3 Bio proposes a radical engineering solution: nonsentient "organ sacks." Instead of relying on scarce research primates, the company aims to grow biological structures containing functional organs but no brain.

Cofounder Alice Gilman describes the approach as designing systems with only necessary components. "It's not missing anything, because we design it to only have the things we want," she says. This precision mirrors software architecture, removing legacy code—in this case, neural pathways capable of pain. The goal involves monkey models for drug toxicity testing, addressing a supply chain crisis after China halted primate exports in 2020. Existing organs-on-chips lack vascular complexity, making these biological models a potential upgrade for scalable data generation.

Immortal Dragons, a longevity fund backing R3, views this as scalable infrastructure for human health. CEO Boyang Wang argues replacement beats repair for aging bodies. Eventually, R3 plans to engineer human versions to supply tissues for transplant, tackling a backlog where 13 people die daily waiting for organs.

The technology leverages stem cells and gene editing to disable brain development genes. While Stanford bioethicist Hank Greely notes the "yuck factor" could hinder public acceptance, the ethical trade-off remains compelling. With over 60,000 primates used in US facilities, demand for standardized, pain-free models is acute.

R3 remains tight-lipped on protocols, though job postings suggest active primate work in Puerto Rico. Backed by Tim Draper, the startup bets on engineering biology to solve shortages traditional methods miss. Whether these bodyoids become standard test beds depends on overcoming biological complexity—and public trust.

Source: Wired science